JP2016506416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506416A5 JP2016506416A5 JP2015552058A JP2015552058A JP2016506416A5 JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5 JP 2015552058 A JP2015552058 A JP 2015552058A JP 2015552058 A JP2015552058 A JP 2015552058A JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- influenza
- derived
- immunogenic composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 239000000185 hemagglutinin Substances 0.000 claims description 8
- 206010022000 influenza Diseases 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 241000713196 Influenza B virus Species 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 5
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 229940126581 whole-virion vaccine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 1
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751077P | 2013-01-10 | 2013-01-10 | |
| US61/751,077 | 2013-01-10 | ||
| PCT/EP2014/050414 WO2014108515A1 (en) | 2013-01-10 | 2014-01-10 | Influenza virus immunogenic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Division JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506416A JP2016506416A (ja) | 2016-03-03 |
| JP2016506416A5 true JP2016506416A5 (enExample) | 2017-02-16 |
Family
ID=49956176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552058A Pending JP2016506416A (ja) | 2013-01-10 | 2014-01-10 | インフルエンザウイルス免疫原性組成物およびその使用 |
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140193484A1 (enExample) |
| EP (1) | EP2943221A1 (enExample) |
| JP (2) | JP2016506416A (enExample) |
| CN (2) | CN109045294A (enExample) |
| AU (2) | AU2014204826A1 (enExample) |
| CA (1) | CA2897752A1 (enExample) |
| HK (1) | HK1214962A1 (enExample) |
| MX (1) | MX2015008847A (enExample) |
| RU (1) | RU2015132962A (enExample) |
| WO (1) | WO2014108515A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63315B1 (sr) | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| CA2840989A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| IN2014CN02114A (enExample) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP4154907A1 (en) | 2012-12-18 | 2023-03-29 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
| DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| CA3001003A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| CA3003103A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CN105664149A (zh) * | 2016-02-24 | 2016-06-15 | 华东理工大学 | 一种多抗原流感通用疫苗及其制备方法 |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| KR102673794B1 (ko) * | 2017-06-15 | 2024-06-11 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| WO2020035609A2 (en) * | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| JP7513614B2 (ja) | 2018-12-20 | 2024-07-09 | インターベット インターナショナル ベー． フェー． | プライム－ブーストワクチン接種レジメン |
| CN114980919A (zh) * | 2019-11-18 | 2022-08-30 | 儿童医学中心公司 | 过度活化驻留树突状细胞的刺激物用于癌症免疫疗法 |
| MX2023000614A (es) | 2020-07-16 | 2023-02-13 | Acuitas Therapeutics Inc | Lipidos cationicos para usarse en nanoparticulas lipidicas. |
| IL313486A (en) | 2021-12-16 | 2024-08-01 | Acuitas Therapeutics Inc | Lipids for use in lipid nanoparticle formulations |
| TWI880664B (zh) * | 2023-03-10 | 2025-04-11 | 財團法人國家衛生研究院 | 流感病毒免疫原性組合物及使用其的方法 |
| AU2024270076A1 (en) * | 2023-05-10 | 2025-11-27 | Seqirus Inc. | Combination vaccine |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6083741A (en) | 1994-11-17 | 2000-07-04 | Imperial College Of Science Technology And Medicine | Internalisation of DNA, using conjugates of poly-l-lysine and an integrin receptor ligand |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
| NZ517903A (en) | 1999-09-24 | 2003-10-31 | Smithkline Beecham Biolog S | One dose intranasal influenza virus vaccine with split influenza viral antigens |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| CA2438942A1 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| AU2003297039B2 (en) * | 2002-12-13 | 2009-03-05 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| DK2311848T3 (da) | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| KR101518309B1 (ko) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| CA2816222A1 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| EP2069376A4 (en) * | 2006-07-21 | 2013-10-16 | Pharmexa Inc | INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS |
| WO2008033966A2 (en) * | 2006-09-12 | 2008-03-20 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| US20100015218A1 (en) * | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| ES2539818T3 (es) * | 2007-08-02 | 2015-07-06 | Biondvax Pharmaceuticals Ltd. | Vacunas contra la gripe multiepitópicas multiméricas |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| BRPI0915487A2 (pt) * | 2008-07-11 | 2017-06-27 | Medimmune Inc | hemaglutina de nfluenza e variantes de neuraminidase |
| US20110280949A1 (en) * | 2008-08-06 | 2011-11-17 | Padma Malyala | Microparticles for use in immunogenic compositions |
| US20110300205A1 (en) * | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
| SI3178490T1 (sl) * | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| ES2443952T3 (es) * | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| WO2011056802A1 (en) * | 2009-11-03 | 2011-05-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Influenza virus recombinant proteins |
| US20130101609A1 (en) * | 2010-01-24 | 2013-04-25 | Novartis Ag | Irradiated biodegradable polymer microparticles |
| BR112013000244A2 (pt) * | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| PL2590676T3 (pl) * | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP3153578A1 (en) * | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| DK3243526T3 (da) * | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| EP2591114B1 (en) * | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| RS63315B1 (sr) * | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| MX341989B (es) | 2010-08-31 | 2016-09-09 | Novartis Ag * | Liposomas pequeños para el suministro de arn que codifica el inmunogeno. |
| JP5908477B2 (ja) | 2010-08-31 | 2016-04-26 | ノバルティス アーゲー | タンパク質をコードするｒｎａのリポソームによる送達に適した脂質 |
| WO2012034025A2 (en) * | 2010-09-09 | 2012-03-15 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| CA2814386C (en) * | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| HRP20190791T1 (hr) * | 2011-01-26 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Režim imuniziranja protiv rsv |
| SI3275892T1 (sl) * | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| CA2840989A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP2729168A2 (en) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| SG10201602456WA (en) | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| CN104105504A (zh) * | 2011-10-11 | 2014-10-15 | 诺华股份有限公司 | 重组多顺反子核酸分子 |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
-
2014
- 2014-01-10 AU AU2014204826A patent/AU2014204826A1/en not_active Abandoned
- 2014-01-10 CA CA2897752A patent/CA2897752A1/en not_active Abandoned
- 2014-01-10 EP EP14700356.0A patent/EP2943221A1/en not_active Withdrawn
- 2014-01-10 RU RU2015132962A patent/RU2015132962A/ru not_active Application Discontinuation
- 2014-01-10 CN CN201811056155.1A patent/CN109045294A/zh active Pending
- 2014-01-10 CN CN201480004387.6A patent/CN104902925A/zh active Pending
- 2014-01-10 US US14/152,397 patent/US20140193484A1/en not_active Abandoned
- 2014-01-10 MX MX2015008847A patent/MX2015008847A/es unknown
- 2014-01-10 WO PCT/EP2014/050414 patent/WO2014108515A1/en not_active Ceased
- 2014-01-10 HK HK16102971.1A patent/HK1214962A1/zh unknown
- 2014-01-10 JP JP2015552058A patent/JP2016506416A/ja active Pending
-
2017
- 2017-11-29 JP JP2017229215A patent/JP2018035195A/ja active Pending
-
2018
- 2018-11-13 AU AU2018260983A patent/AU2018260983A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506416A5 (enExample) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| WO2016109792A8 (en) | Novel multivalent nanoparticle-based vaccines | |
| JP2019526580A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| JP2014503206A5 (enExample) | ||
| JP2019530462A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| WO2020035609A3 (en) | Immunogenic compositions and uses thereof | |
| JP2017158561A5 (enExample) | ||
| JP2014532620A5 (enExample) | ||
| JP2015522540A5 (enExample) | ||
| JP2009539965A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| EA201990718A1 (ru) | Векторы аденовируса собачьих | |
| Slütter et al. | Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine | |
| JP2020528911A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2016520530A5 (enExample) | ||
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| FI3656395T3 (fi) | Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan | |
| JP2019531293A5 (enExample) | ||
| Fisher et al. | Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination | |
| JP2018501258A5 (enExample) |